We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
We Like These Underlying Return On Capital Trends At Merit Medical Systems (NASDAQ:MMSI)
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll want to notice a trend of growing return on capital employed (ROCE) and alongside that, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. So when we looked at Merit Medical Systems (NASDAQ:MMSI) and its trend of ROCE, we really liked what we saw.
如果我們想要找到潛在的多倍股,通常會有一些潛在的趨勢可以提供線索。通常,我們會注意到資本利用率(ROCE)增長的趨勢,以及資本利用率的擴大。基本上,這意味着公司有盈利的舉措可以繼續投資,這是一個複利機器的特徵。所以當我們看到Merit Medical Systems(納斯達克:MMSI)及其ROCE的趨勢時,我們真的很喜歡我們看到的內容。
What Is Return On Capital Employed (ROCE)?
我們對 Enphase Energy 的資本僱用回報率的看法:正如我們上面看到的,Enphase Energy 的資本回報率沒有提高,但它正在重新投資於業務。投資者必須認爲未來會有更好的前景,因爲股票表現良好,使持股五年以上的股東獲得了 690% 的收益。最終,如果基本趨勢持續存在,我們不會對它成爲一隻多頭股持有期很久很有信心。
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. To calculate this metric for Merit Medical Systems, this is the formula:
只是爲了澄清,如果你不確定,ROCE是評估公司在其業務中投入的資本所賺取的稅前收入(以百分比表示)的衡量標準。要爲Merit Medical Systems計算這個指標,這是公式:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
資產僱用回報率(ROCE)是指企業利潤,即企業稅前利潤除以企業投入的總資本(負債加股權)。如果ROCE高於企業財務成本的承受能力,那麼企業就會創造出更多的價值。
0.07 = US$153m ÷ (US$2.4b - US$201m) (Based on the trailing twelve months to September 2024).
0.07 = 15300萬美元 ÷(24億美元 - 2.01億美元)(基於2024年9月的過去十二個月)。
Therefore, Merit Medical Systems has an ROCE of 7.0%. In absolute terms, that's a low return and it also under-performs the Medical Equipment industry average of 8.8%.
因此,Merit Medical Systems的ROCE爲7.0%。就絕對值而言,這是一個較低的回報,也低於醫療設備行業平均水平8.8%。
In the above chart we have measured Merit Medical Systems' prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Merit Medical Systems .
在上面的圖表中,我們測量了merit medical systems的先前ROCE與其先前業績,但未來可能更重要。 如果您想了解分析師對未來的預測,請查看我們針對merit medical systems的免費分析師報告。
How Are Returns Trending?
綜合上述,Cimpress非常有效地提高了其資本利用率所產生的回報。考慮到股票過去五年保持穩定,如果其他指標也不錯,則可能存在機會。因此,進一步研究這家公司並確定這些趨勢是否會持續是合理的。
Even though ROCE is still low in absolute terms, it's good to see it's heading in the right direction. The numbers show that in the last five years, the returns generated on capital employed have grown considerably to 7.0%. The amount of capital employed has increased too, by 35%. So we're very much inspired by what we're seeing at Merit Medical Systems thanks to its ability to profitably reinvest capital.
儘管ROCE在絕對值上仍然較低,但看到它朝着正確的方向發展是好事。 數字顯示,在過去的五年中,資本利用率實現的回報率大幅增長至7.0%。 資本利用率也增加了35%。 因此,我們對merit medical systems的盈利能力重新投資資本的能力感到非常振奮。
What We Can Learn From Merit Medical Systems' ROCE
我們從merit medical systems的ROCE中可以學到什麼
All in all, it's terrific to see that Merit Medical Systems is reaping the rewards from prior investments and is growing its capital base. And a remarkable 270% total return over the last five years tells us that investors are expecting more good things to come in the future. Therefore, we think it would be worth your time to check if these trends are going to continue.
總的來說,看到merit medical systems正在收穫先前投資的回報並在擴大其資本基礎是非常棒的。 過去五年的總回報達到驚人的270%,告訴我們投資者希望未來會有更多好事發生。 因此,我們認爲值得您花時間查看這些趨勢是否會持續。
On the other side of ROCE, we have to consider valuation. That's why we have a FREE intrinsic value estimation for MMSI on our platform that is definitely worth checking out.
在ROCE的另一面,我們必須考慮估值。 這就是爲什麼我們在平台上爲merit medical systems提供了一個免費的內在價值估算,絕對值得一看。
While Merit Medical Systems may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.
儘管merit medical systems目前並非賺取最高回報,但我們已經整理了一份目前獲得超過25%股本回報的公司名單。 點擊此處查看這份免費名單。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。
譯文內容由第三人軟體翻譯。